1. Short title This Act may be cited as the Understanding COVID–19 Subsets and ME/CFS Act or the U.C.S. ME/CFS Act . 2. Findings Congress finds the following: (1) As of May 27, 2020, the virus that causes COVID–19 has infected 1.7 million Americans, many of whom may never recover, and has caused over 100,000 deaths. (2) Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a serious, chronic, and multisystemic disease associated with survivors of viral infections. (3) Subsets of COVID–19 patients are presenting with ME/CFS symptoms, such as brain inflammation, and experts expect a significant increase of ME/CFS cases in the next two years in the United States following the COVID–19 epidemic. (4) ME/CFS is characterized by chronic or lifelong symptoms across multiple body systems including post-exertional malaise (PEM), brain inflammation, fever, pain, neurological, immune and cognitive dysfunction, and swollen glands or tender lymph nodes which are most likely to appear following a viral infection, like coronaviruses, Epstein-Barr, or Q-River fever. (5) The severity of both COVID–19 and ME/CFS ranges from mild to completely debilitating and in some cases can be lethal. (6) The cause of ME/CFS is unknown. There is no diagnostic test for ME/CFS, and there is no treatment for ME/CFS that is approved by the Food and Drug Administration. (7) Physicians are not sufficiently educated on the proper diagnosis of COVID–19 subsets, ME/CFS, or current treatments for ME/CFS. This leads to excess health care costs, errors in treatments, and harm to patients. (8) Patients with ME/CFS frequently suffer for years before receiving an accurate diagnosis and are often given harmful treatment recommendations exposing them to unnecessary and costly tests and procedures, as well as needless suffering and expense. (9) The economic impact of ME/CFS is high. The annual cost in the United States for ME/CFS is estimated to be between $17,000,000,000 and $24,000,000,000 in medical expenditures and lost productivity. The